• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nykode Therapeutics

Less than 1K followers

NYKD

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview
Investor consensus

Nykode Therapeutics is a biotechnology company. The company specializes in the research and development of immunological therapies and vaccines. The solutions are mainly used for the treatment of patients with cancer and other serious health conditions that require long-term treatment. The largest operations are in the European market.

Read more
Market cap
-
Turnover
-
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
26/8
2026

Interim report Q2'26

25/11
2026

Interim report Q3'26

24/2
2027

Annual report '26

All
Press releases
ShowingAll content types

Regulatory press release5/27/2026, 5:00 AM

Nykode Therapeutics - Quarterly Report Q1 2026

Nykode Therapeutics
Regulatory press release5/18/2026, 9:34 AM

Nykode Therapeutics - Invitation to Q1 2026 Financial Results Presentation

Nykode Therapeutics
Regulatory press release5/13/2026, 9:15 AM

Nykode Therapeutics ASA - Minutes of Annual General Meeting

Nykode Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/7/2026, 11:54 AM

NYKD: Nykode Therapeutics Doses First Patient in Abili-T Phase II Randomized Trial evaluating Abi-suva in HPV16-Positive, PD-L1-Positive Recurrent or Metastatic Head and Neck Cancer Patients

Nykode Therapeutics
Regulatory press release4/30/2026, 6:30 AM

NYKD: Nykode Therapeutics Presents AI-Powered Immunotherapy Design Capabilities at BioPharma Drug Discovery Nexus 2026

Nykode Therapeutics
Regulatory press release4/21/2026, 6:30 AM

Nykode Therapeutics ASA - Notice of Annual General Meeting

Nykode Therapeutics
Regulatory press release4/20/2026, 10:00 AM

NYKD: Nykode Therapeutics Presents Additional Immunogenicity Data from VB-C-03 Trial at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Nykode Therapeutics
Regulatory press release4/17/2026, 5:30 AM

Nykode Therapeutics - Annual Report 2025

Nykode Therapeutics
Regulatory press release3/20/2026, 1:45 PM

NYKD: Nykode Therapeutics Highlights Robust Immunogenicity and Promising Clinical Activity for Abi-Suva at ICHNO 2026

Nykode Therapeutics
Regulatory press release3/18/2026, 7:30 AM

NYKD: Nykode Therapeutics Announces Upcoming Presentations at AACR 2026 and NextGen Biomed 2026

Nykode Therapeutics
Regulatory press release3/9/2026, 7:30 AM

NYKD: Nykode Therapeutics to Present at DNB Carnegie Conference on March 10, 2026

Nykode Therapeutics
Regulatory press release3/3/2026, 7:40 AM

NYKD: Nykode Therapeutics to Present New Data and Participate in Panel Discussion at the 9th Annual Antigen-Specific Immune Tolerance Summit (ASIT)

Nykode Therapeutics
Regulatory press release2/25/2026, 6:00 AM

Nykode Therapeutics - Quarterly Report Q4 2025

Nykode Therapeutics
Regulatory press release2/24/2026, 10:45 AM

NYKD: Nykode Therapeutics Announces New Interim Data from the VB-C-03 Trial Showing Encouraging Anti-Tumor Activity and Tolerability of Abi-suva (VB10.16)

Nykode Therapeutics
Regulatory press release2/11/2026, 12:45 PM

Nykode Therapeutics - Invitation to Q4 2025 Financial Results Presentation

Nykode Therapeutics
Regulatory press release1/30/2026, 9:44 PM

Nykode Therapeutics - Grant of share options

Nykode Therapeutics
Regulatory press release1/21/2026, 10:55 AM

Nykode Therapeutics ASA - Minutes of Extraordinary General Meeting

Nykode Therapeutics
Regulatory press release12/30/2025, 4:49 PM

NYKD: Financial calendar

Nykode Therapeutics
Regulatory press release12/19/2025, 1:45 PM

NYKD: Nykode Therapeutics to Present Interim Data from the VB-C-03 trial at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) on March 20, 2026

Nykode Therapeutics
Regulatory press release12/18/2025, 6:00 AM

Nykode Therapeutics ASA - Notice of Extraordinary General Meeting

Nykode Therapeutics